Natera, Inc. $NTRA Shares Purchased by TD Asset Management Inc

TD Asset Management Inc raised its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 9.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 129,606 shares of the medical research company’s stock after buying an additional 11,658 shares during the period. TD Asset Management Inc owned about 0.09% of Natera worth $20,863,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Integrated Wealth Concepts LLC increased its holdings in Natera by 6.6% during the 1st quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock worth $221,000 after purchasing an additional 96 shares during the last quarter. NewEdge Advisors LLC grew its position in shares of Natera by 68.3% during the 1st quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock valued at $644,000 after buying an additional 1,847 shares during the last quarter. Focus Partners Wealth grew its holdings in shares of Natera by 8.6% during the first quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock valued at $847,000 after purchasing an additional 474 shares during the last quarter. Sivia Capital Partners LLC bought a new stake in Natera in the second quarter valued at $298,000. Finally, Envestnet Asset Management Inc. increased its holdings in shares of Natera by 5.9% in the 2nd quarter. Envestnet Asset Management Inc. now owns 172,022 shares of the medical research company’s stock worth $29,061,000 after acquiring an additional 9,651 shares during the period. Institutional investors and hedge funds own 99.90% of the company’s stock.

Key Stories Impacting Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Quarterly beat — Natera reported Q4 revenue of $665.5M and GAAP EPS of $0.35, well ahead of street estimates (revenue ~$600.7M, EPS loss consensus). The beat supports near-term growth expectations and underpins the stock’s recent strength. Natera Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Favorable clinical data — New Signatera MRD data presented at ASCO GU highlight potential utility across genitourinary cancers (including bladder preservation), which may expand clinical adoption and long-term revenue for Natera’s oncology franchise. Signatera MRD Data at ASCO GU
• Positive Sentiment: Trial results — Natera reported results from the SINERGY trial, another clinical datapoint that could support commercial adoption of its assays. Natera Announces Results From the SINERGY Trial
• Positive Sentiment: Analyst upgrades/targets — Robert W. Baird raised its price target to $257 (outperform) and Wells Fargo raised its target to $215 (equal weight), signaling some sell-side confidence in upside from current levels. Benzinga – Analyst Price Target Changes
• Neutral Sentiment: Full-year revenue guidance roughly in line with consensus — Management issued FY2026 revenue guidance (roughly $2.6B–$2.7B), which appears consistent with street expectations and reduces upside surprise potential from guidance alone. (See Q4 release for guidance details.) Natera Reports Fourth Quarter and Full Year 2025 Financial Results
• Neutral Sentiment: Analyst consensus — Aggregated analyst coverage remains constructive (average “Moderate Buy”), which supports medium-term expectations but doesn’t preclude short-term volatility. Analyst Average Rating
• Negative Sentiment: Valuation and fundamentals concerns — Despite the beat, Natera still shows negative net margin and negative return on equity on a GAAP basis; combined with a high market capitalization and a recent run-up toward 52-week highs, investors may be taking profits. MarketBeat Q4 Coverage
• Negative Sentiment: Heavy intraday volume and selling pressure — Trading volume was well above average, consistent with a distribution day where some holders trimmed positions after the company’s strong quarter; that drove the stock lower despite the positives. (See intraday volume and price action for context.)

Natera Stock Performance

Shares of NASDAQ:NTRA opened at $208.04 on Friday. The stock’s 50-day moving average is $226.52 and its 200-day moving average is $203.85. Natera, Inc. has a 52-week low of $125.38 and a 52-week high of $256.36. The company has a market cap of $28.78 billion, a P/E ratio of -135.97 and a beta of 1.64.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.81. The company had revenue of $665.50 million during the quarter, compared to analysts’ expectations of $600.68 million. Natera had a negative return on equity of 16.71% and a negative net margin of 9.03%.During the same period in the prior year, the business earned ($0.41) earnings per share. As a group, equities analysts predict that Natera, Inc. will post -1.49 EPS for the current year.

Insider Buying and Selling at Natera

In other Natera news, insider John Fesko sold 3,594 shares of the firm’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $231.02, for a total transaction of $830,285.88. Following the completion of the transaction, the insider owned 178,081 shares in the company, valued at $41,140,272.62. This trade represents a 1.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Solomon Moshkevich sold 1,639 shares of the company’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $230.77, for a total transaction of $378,232.03. Following the sale, the insider directly owned 137,847 shares in the company, valued at $31,810,952.19. This represents a 1.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 368,119 shares of company stock worth $85,956,782. Insiders own 5.63% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on NTRA. Morgan Stanley upped their price objective on shares of Natera from $220.00 to $265.00 and gave the stock an “overweight” rating in a report on Monday, December 1st. Stephens boosted their price target on shares of Natera from $197.00 to $235.00 and gave the stock an “overweight” rating in a research report on Thursday, November 13th. Evercore raised their price objective on shares of Natera from $190.00 to $250.00 and gave the company an “outperform” rating in a research report on Friday, November 7th. Zacks Research upgraded shares of Natera from a “strong sell” rating to a “hold” rating in a report on Thursday, January 1st. Finally, TD Cowen restated a “buy” rating on shares of Natera in a research report on Wednesday, January 7th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $254.47.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.